Drug Details
CD24Fc is a first-in-class recombinant fusion protein that targets a novel immune pathway checkpoint.
Study Purpose
The study is designed as a randomized, placebo-controlled, double blind, multicenter, Phase III trial to compare two COVID-19 treatment regimens in hospitalized adult subjects who are diagnosed with severe COVID 19 and absolute lymphocyte counts ≤ 800/mm^3 in peripheral blood.
